Cargando…
Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes
Chemosensitizer or combined chemotherapy can sensitize cancer cells to therapy and minimize drug resistance. We reveal that levofloxacin has broad-spectrum anticancer activity. Here we report that combination of levofloxacin and cisplatin further enhanced cytotoxicity in cancer cells by further prom...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391551/ https://www.ncbi.nlm.nih.gov/pubmed/35984577 http://dx.doi.org/10.1007/s12672-022-00541-x |
_version_ | 1784770875237597184 |
---|---|
author | He, Xiaoqiong Yao, ·Qian Fan, Dan You, Yutong Lian, Wenjing Zhou, Zhangping Duan, Ling |
author_facet | He, Xiaoqiong Yao, ·Qian Fan, Dan You, Yutong Lian, Wenjing Zhou, Zhangping Duan, Ling |
author_sort | He, Xiaoqiong |
collection | PubMed |
description | Chemosensitizer or combined chemotherapy can sensitize cancer cells to therapy and minimize drug resistance. We reveal that levofloxacin has broad-spectrum anticancer activity. Here we report that combination of levofloxacin and cisplatin further enhanced cytotoxicity in cancer cells by further promotion of apoptosis. Levofloxacin concentration-dependently promoted the inhibition of clone formation in cancer cells treated by cisplatin, and their combination further suppressed the tumor growth in mice. Levofloxacin and cisplatin co-regulated genes in directions supporting the enhancement of anticancer efficacy, of which, THBS1, TNFAIP3, LAPTM5, PI3 and IL24 were further upregulated, NCOA5, SRSF6 and SFPQ were further downregulated. Out of the 24 apoptotic pathways significantly enriched in the combination group, TNFAIP3, THBS1, SRSF6 and SFPQ overlapped in 14, 13, 3 and 1 pathway respectively. Jak-STAT/Cytokine-cytokine receptor interaction pathway network and extrinsic apoptotic signaling pathway were significantly enriched in levofloxacin group, cisplatin group and combination group. Jak-STAT/Cytokine-cytokine receptor interaction/Focal adhesion/EMC-receptor interaction pathway network was significantly enriched in the combination group, and IL24 and THBS1 were the overlapped genes. In conclusion, enhancement of anticancer efficacy in combination group was associated with the further regulation of THBS1, TNFAIP3, LAPTM5, PI3, IL24 and NCOA5, SFPQ, SRSF6. Targeting of Jak-STAT/Cytokine-cytokine receptor interaction/Focal adhesion/EMC-receptor interaction pathway network was correlated to the enhancement. With additional benefit to cancer patients for treatment or prophylaxis of an infectious syndrome, levofloxacin can benefit cancer chemotherapy no matter it is used independently or used with other chemotherapeutic drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00541-x. |
format | Online Article Text |
id | pubmed-9391551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-93915512022-08-21 Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes He, Xiaoqiong Yao, ·Qian Fan, Dan You, Yutong Lian, Wenjing Zhou, Zhangping Duan, Ling Discov Oncol Research Chemosensitizer or combined chemotherapy can sensitize cancer cells to therapy and minimize drug resistance. We reveal that levofloxacin has broad-spectrum anticancer activity. Here we report that combination of levofloxacin and cisplatin further enhanced cytotoxicity in cancer cells by further promotion of apoptosis. Levofloxacin concentration-dependently promoted the inhibition of clone formation in cancer cells treated by cisplatin, and their combination further suppressed the tumor growth in mice. Levofloxacin and cisplatin co-regulated genes in directions supporting the enhancement of anticancer efficacy, of which, THBS1, TNFAIP3, LAPTM5, PI3 and IL24 were further upregulated, NCOA5, SRSF6 and SFPQ were further downregulated. Out of the 24 apoptotic pathways significantly enriched in the combination group, TNFAIP3, THBS1, SRSF6 and SFPQ overlapped in 14, 13, 3 and 1 pathway respectively. Jak-STAT/Cytokine-cytokine receptor interaction pathway network and extrinsic apoptotic signaling pathway were significantly enriched in levofloxacin group, cisplatin group and combination group. Jak-STAT/Cytokine-cytokine receptor interaction/Focal adhesion/EMC-receptor interaction pathway network was significantly enriched in the combination group, and IL24 and THBS1 were the overlapped genes. In conclusion, enhancement of anticancer efficacy in combination group was associated with the further regulation of THBS1, TNFAIP3, LAPTM5, PI3, IL24 and NCOA5, SFPQ, SRSF6. Targeting of Jak-STAT/Cytokine-cytokine receptor interaction/Focal adhesion/EMC-receptor interaction pathway network was correlated to the enhancement. With additional benefit to cancer patients for treatment or prophylaxis of an infectious syndrome, levofloxacin can benefit cancer chemotherapy no matter it is used independently or used with other chemotherapeutic drugs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00541-x. Springer US 2022-08-19 /pmc/articles/PMC9391551/ /pubmed/35984577 http://dx.doi.org/10.1007/s12672-022-00541-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research He, Xiaoqiong Yao, ·Qian Fan, Dan You, Yutong Lian, Wenjing Zhou, Zhangping Duan, Ling Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title | Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title_full | Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title_fullStr | Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title_full_unstemmed | Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title_short | Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
title_sort | combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391551/ https://www.ncbi.nlm.nih.gov/pubmed/35984577 http://dx.doi.org/10.1007/s12672-022-00541-x |
work_keys_str_mv | AT hexiaoqiong combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT yaoqian combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT fandan combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT youyutong combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT lianwenjing combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT zhouzhangping combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes AT duanling combinationoflevofloxacinandcisplatinenhancesanticancerefficacyviacoregulationofeightcancerassociatedgenes |